--- title: Perineural Injection and Supraspinatus Tendenopathy nct_id: NCT03942640 overall_status: UNKNOWN phase: NA sponsor: Mansoura University study_type: INTERVENTIONAL primary_condition: Supraspinatus Tendinopathy countries: Egypt canonical_url: "https://parkinsonspathways.com/agent/trials/NCT03942640.md" clinicaltrials_gov: "https://clinicaltrials.gov/study/NCT03942640" ct_last_update_post_date: 2019-08-14 last_seen_at: "2026-05-12T06:02:46.085Z" source: ClinicalTrials.gov (mirrored, no enrichment) --- # Perineural Injection and Supraspinatus Tendenopathy **Official Title:** Perineural Injection Therapy in Treatment of Chronic Supraspinatous Tendinopathy :A Randomized Clinical Trial Among Egyptian Patients . **NCT ID:** [NCT03942640](https://clinicaltrials.gov/study/NCT03942640) ## Key Facts - **Status:** UNKNOWN - **Phase:** NA - **Study Type:** INTERVENTIONAL - **Target Enrollment:** 60 - **Lead Sponsor:** Mansoura University - **Conditions:** Supraspinatus Tendinopathy - **Start Date:** 2019-06-01 - **Completion Date:** 2021-01-01 - **CT.gov Last Update:** 2019-08-14 ## Brief Summary Atotal of 150 consecutive patients with chronic supraspinatous tendinopathy were invited to participate in the study .patients were recruited from the out patient clinic of rheumatology and rehabilitation department,Mansoura university hospital a. perineural injection therapy group (subcutaneous prolotherapy) This group included 30 patients aged from 18 to 60 years Deep prolotherapy injection group The injection fluid contain 1 ml of 255 glucose and 1ml of lidocaine. The pathological area of the supraspinatous tendon was identified and graded using ultrasound pathology rating scale guided by ultrasonography (Simens Acuson p300 machine) Proper preparation with antiseptic solution of skin overlying the point of injection . ## Detailed Description Baseline Evaluation All patients were subjected to the following: 1. Thorough History Taking 1. Personal history: collected data include: age, sex, marital status, handedness, special habits and the current occupation. 2. Complaint in the patient's own words. 3. Present History he current symptoms, mode of onset, duration, , factors that may aggravate or relieve pain Characters of pain (dull aching,sharp pain ,burning sensation ,parasthesia). Distribution of pain . Review of systems: symptoms related to rheumatic conditions in particular conditions with predilection for shoulder joint affection. Symptoms suggestive of medical disorders e.g. diabetes mellitus or thyroid dysfunction. 4. Past History Previous significant trauma(direct or occupational) orsugery to shoulder. Previous steroid injection to the shoulder. Previous injection of any type of regenerative medicine (as prp) 2. Thorough General Examination 1. General condition. 2. Vital signs (pulse, blood pressure, respiratory rate, body temperature) 3. Examination of systems (chest,cardiovascular,abdominal,neurological) to identify medical condition that may cause shoulder pain. 3-Muscloskeletal examination 1. General muscloskeletal examination Examination of all joints for : I.deformity,visible swelling or muscle atrophy II.Palpation for tenderness,warmth,palpable swelling either bony enlargement or synovial effusion. III.Abnormalities in range of motion. IV.Diffuse muscloskeletal pain. V.Abnormalities of gait. ## Eligibility - **Minimum age:** 18 Years - **Maximum age:** 20 Years - **Sex:** ALL - **Healthy Volunteers:** No ``` Inclusion Criteria: Patients with supraspinatous tendinopathy Exclusion Criteria: -Shoulder joint instability omplete rotator cuff tear Adhesive capsulitis Septic arthritis Malignancy Coagulopathy Connective tissue diseases Spondyloarthropathies Previous corticosteroid injection in the last six months. Previous other forms of regenerative injection therapy (e.g prp injection therapy) in the last six mo ``` ## Arms - **perineural injection group** (OTHER) — perineural injection therapy group (subcutaneous prolotherapy) This group included 30 patients aged from 18 to 60 years Buffered glucose preparation : 2.4 ml of Na Bicarbonate 8.4% are mixed with 500ml dextrose 5%. Patients received 8 weekly injection sessions at sites of chronic constriction injurey of the following nerves : Suprascapular nerve.. - **deepprolotherapy group** (OTHER) — Deep prolotherapy injection group The injection fluid contain 1 ml of 255 glucose and 1ml of lidocaine. The pathological area of the supraspinatous tendon was identified and graded using ultrasound pathology rating scale guided by ultrasonography (Simens Acuson p300 machine) Proper preparation with antiseptic solution of skin overlying the point of injection . ## Interventions - **subctaneous perineural injection** (OTHER) — Buffered glucose preparation : 2.4 ml of Na Bicarbonate 8.4% are mixed with 500ml dextrose 5%. Patients received 8 weekly injection - **deep prolotherapy** (OTHER) — The injection fluid contain 1 ml of 255 glucose and 1ml of lidocaine ## Primary Outcomes - **change of pain from baseline** _(time frame: immediately before injection,2 monthes after injection,3 monthes after injection)_ — The VAS-pain score is composed of a continuous horizontal line. This line is 100 mm in length. To measure the intensity of pain, the score is anchored by (0 score = no pain) at one end and (100 score = worst imaginable pain) on the other end. The patient places a mark to the VAS line at the point which represents the intensity of his pain - **change of range of motion from base line** _(time frame: immediately before injection,2 monthes after injection,3 monthes after injection)_ — III.Examination of passive and active range of motion using goniometer based on the description of norkin and white as following * Abduction ;170 * Adduction :50 * Flexion :165 * Extension:60 * Internal rotation at 90 abduction :70 * External rotation at 90 abduction :100 ## Secondary Outcomes - **change of function from base line** _(time frame: immediately before injection,2 monthes after injection,3 monthes after injection)_ ## Locations (1) - Reham Magdy Shaat, Al Mansurah, Dakahlia Provence, Egypt — _RECRUITING_ ## Recent Field Changes (last 30 days) - `status.overallStatus` — added _(2026-05-12)_ - `status.primaryCompletionDate` — added _(2026-05-12)_ - `status.completionDate` — added _(2026-05-12)_ - `status.lastUpdatePostDate` — added _(2026-05-12)_ - `design.phases` — added _(2026-05-12)_ - `design.enrollmentCount` — added _(2026-05-12)_ - `eligibility.criteria` — added _(2026-05-12)_ - `eligibility.minAge` — added _(2026-05-12)_ - `eligibility.maxAge` — added _(2026-05-12)_ - `eligibility.sex` — added _(2026-05-12)_ - `outcomes.primary` — added _(2026-05-12)_ - `outcomes.secondary` — added _(2026-05-12)_ - `armsInterventions.arms` — added _(2026-05-12)_ - `armsInterventions.interventions` — added _(2026-05-12)_ - `sponsor.lead` — added _(2026-05-12)_ - `results.hasResults` — added _(2026-05-12)_ - `locations.reham magdy shaat|al mansurah|dakahlia provence|egypt` — added _(2026-05-12)_ --- *Canonical: https://parkinsonspathways.com/agent/trials/NCT03942640.md* *Source data (authoritative): https://clinicaltrials.gov/study/NCT03942640* *This page is a raw mirror with no AI summary, no editorial enrichment, and no Parkinson's-specific filtering.*